2026-03-17 12:32:55
CNBX Pharmaceuticals Inc. Secures $45,000 Promissory Note for Working Capital
Expected Stock impact: Slightly Positive
On March 10, 2026, CNBX Pharmaceuticals Inc. executed a non-convertible Promissory Note with 3i L.P., a Delaware Limited Partnership, for the amount of $45,000. This financial instrument is due on July 1, 2026, and carries a simple interest rate of 5% per annum. The company intends to utilize the proceeds from this note for immediate working capital purposes and expenditures. This financing arrangement is expected to provide CNBX with the necessary liquidity to support its ongoing operations and strategic initiatives. The terms of the note indicate a straightforward repayment structure, which may enhance the company's financial stability in the short term. However, the reliance on debt financing could lead to potential dilution concerns if the company seeks to raise additional capital in the future. Overall, this development is viewed positively as it demonstrates CNBX's proactive approach to securing funding amidst its operational needs.
